Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 14930
  • Home
  • Print this page
  • Email this page

   Table of Contents      
Year : 2007  |  Volume : 55  |  Issue : 6  |  Page : 457-458

Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks

Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Date of Submission08-Aug-2006
Date of Acceptance28-Sep-2006

Correspondence Address:
Amod Gupta
Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh - 160 012
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0301-4738.36482

Rights and Permissions

Angioid streaks are crack-like dehiscences in the Bruch's membrane, which predispose to the development of a choroidal neovascular membrane (CNVM) that carries a poor visual outcome. We report successful treatment in a 25-year-old woman with bilateral angioid streaks and subfoveal CNVM in the left eye who received two doses of intravitreal bevacizumab (1.25 mg) injections six weeks apart, resulting in rapid regression of the CNVM.

Keywords: Angioid streaks, intravitreal bevacizumab, subfoveal choroidal neovascular membrane

How to cite this article:
Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol 2007;55:457-8

How to cite this URL:
Sachdev N, Vishwanathan K, Gupta V, Singh R, Gupta A. Intravitreal bevacizumab (Avastin) in choroidal neovascular membrane in angioid streaks. Indian J Ophthalmol [serial online] 2007 [cited 2020 Aug 4];55:457-8. Available from: http://www.ijo.in/text.asp?2007/55/6/457/36482

Angioid streaks are the result of a crack-like dehiscence in the Bruch's membrane, which itself is brittle and calcified, and are seen as linear gray lesions radiating from the peripapillary area. [1] Visual impairment often occurs as a result of a subfoveal choroidal neovascular membrane (CNVM) with subsequent serous and hemorrhagic detachment of the overlying neurosensory retina. These neovascular membranes associated with angioid streaks present a major challenge in management. Argon laser treatment of the CNVM shows a drop in visual acuity (VA) with high rates of recurrence and persistence. [2] Photodynamic therapy using verteporfin has been tried extensively in such eyes with very poor results with most eyes undergoing enlargement and disciform transformation of the neovascularization process. [3],[4] Poor success and high recurrence rates have been seen after submacular surgery for removal of CNVM in such cases. [5] In this case report, we present a case of CNVM associated with angioid streaks treated with intravitreal bevacizumab, an anti-vascular endothelial growth factor (VEGF) molecule.

  Case Report Top

A 25-year-old woman presented with progressive blurring of vision in the left eye of two months duration. There was no history of any systemic illness or previous ocular trauma. Ocular examination revealed a best corrected VA of 20/20 in the right eye and 20/40 in the left eye. The pupillary reactions as well as the slit-lamp biomicroscopic examination of the anterior segment were normal in both the eyes. The posterior segment findings included bilateral, multiple, grayish, subretinal, linear branching streaks extending centrifugally from the peripapillary area and multiple areas of "Peau d'orange" pigmentary changes in the temporal midperipheral fundus. In the left eye one of these streaks passed through the fovea and was associated with a small, grayish, subfoveal lesion with a surrounding bleed [Figure - 1]A.

Fundus fluorescein angiography showed transmission hyperfluorescence corresponding to the linear streaks and an area of expanding hyperfluorescence, with late leakage in the subfoveal location in the left eye [Figure - 1]B. Optical coherence tomography (OCT) confirmed the presence of a subfoveal CNVM with a central retinal thickness (CRT) of 392 microns in the left eye [Figure - 2]A.

A detailed systemic workup revealed the presence of multiple hyperpigmented papules on the back of the neck with a highly elastic skin, suggestive of pseudoxanthoma elasticum.

After an informed consent, 1.25 mg intravitreal bevacizumab (Avastin TM , Genetech INA, California, USA) was injected in the left eye under aseptic conditions. Post-injection, her best corrected visual acuity improved to 20/30 and the CRT on OCT reduced to 331 microns at one week and to 211 microns at six weeks. Fundus fluorescein angiogram confirmed reduction in leakage [Figure - 1]C.

A second dose of intravitreal bevacizumab (1.25 mg) was repeated six weeks after the first injection. Two weeks after the second dose, her best corrected visual acuity improved to 20/20. Fluorescein angiogram confirmed total absence of any leakage [Figure - 1]D with CRT of 190 microns on OCT [Figure - 2]B.

  Discussion Top

Most patients with angioid streaks may remain asymptomatic till development of subfoveal CNVM or a choroidal rupture which carries an extremely poor visual prognosis whether treated or not. [2],[3],[4],[5]

Recently, vascular endothelial growth factor (VEGF) has been implicated in the pathogenesis of CNVM. [6] Bevacizumab is a humanized monoclonal antibody that inhibits all isoforms of VEGF and is FDA-approved for the treatment of colorectal cancer. [7] Recently, bevacizumab has been used to treat CNVM due to age-related macular degeneration (ARMD). [8],[9] These exudative ARMD patients treated with two or three injections of intravitreal bevacizumab showed marked improvement in visual acuity with reduction in angiographic leakage and CRT after 12 weeks of follow-up. These studies showed no untoward effects even after three injections.

As development of CNVM in angioid streaks may also involve similar mechanisms of neovascularization, it prompted us for a trial of the above drug. A literature review using MEDLINE failed to reveal any mention of a case of choroidal neovascularization due to angioid streaks treated with intravitreal bevacizumab. This case illustrates that intravitreal bevacizumab has a possible role in the treatment of the above condition with regression of neovascular membrane and subsequent visual improvement, although a much longer follow-up and a large prospective study is required to reach a conclusive result.

  References Top

Shields JA, Federman JL, Tomer TL, Annesley WH Jr. Angioid streaks. I. Ophthalmoscopic variations and diagnostic problems. Br J Ophthalmol 1975;59:257-66.  Back to cited text no. 1
Lim JI, Bressler NM, Marsh MJ, Bressler SB. Laser treatment of choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 1993;116:414-23.  Back to cited text no. 2
Shaikh S, Ruby AJ, Williams GA. Photodynamic therapy using verteporfin for choroidal neovascularization in angioid streaks. Am J Ophthalmol 2003;135:1-6.  Back to cited text no. 3
Arias L, Pujol O, Rubio M, Caminal J. Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefes Arch Clin Exp Ophthalmol 2006;244:753-7.  Back to cited text no. 4
Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994;101:1384-96.  Back to cited text no. 5
Hangai M, Murata T, Miyawaki N, Spee C, Lim JI, He S, et al . Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2001;42:1617-25.  Back to cited text no. 6
Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al . Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006;24:3354-60.  Back to cited text no. 7
Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006;142:1-9.  Back to cited text no. 8
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006;113:363-72.  Back to cited text no. 9


  [Figure - 1], [Figure - 2]

This article has been cited by
1 Membrana neovascular subretiniana asociada a estrías angioides tratada con bevacizumab intravítreo
A. García-López,C. González-Castaño
Archivos de la Sociedad Española de Oftalmología. 2013;
[Pubmed] | [DOI]
Retina. 2010; 30(5): 748
[Pubmed] | [DOI]
3 Verteporfin photodynamic therapy combined with intravitreal triamcinolone for choroidal neovascularization due to angioid streaks
Pece, A., Russo, G., Ricci, F., Isola, V., Introini, U., Querques, G.
Clinical Ophthalmology. 2010; 4(1): 525-530
4 Clinical manifestations of idiopathic angioid streaks
Gao, Y., Jiang, X., Zhang, Y., Liu, F., Song, R.
Chinese Ophthalmic Research. 2010; 28(4): 342-346
5 Treatment of angioid streaks with Bevacizumab | [Liečba Angioid streaks (lakové trhliny) pomocou anti-VEGF]
Černák, M., Markovic, O., Černák, A.
Ceska a Slovenska Oftalmologie. 2010; 66(2): 72-75
6 Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum
Myung, J.S., Bhatnagar, P., Spaide, R.F., Klancnik Jr., J.M., Cooney, M.J., Yannuzzi, L.A., Freund, K.B.
Retina. 2010; 30(5): 748-755
Ioannis D Ladas, Athanasios I Kotsolis, Dimitrios S Ladas, Maria Niskopoulou, Ilias Georgalas, Dimitrios Papakonstantinou, Alexandros A Rouvas
Retina. 2010; 30(8): 1185
[VIEW] | [DOI]
Francesco Boscia, Salvatore Cillino, Maria Vadalà, Alfredo Pece, Stefano Cipolla, Carla Monteleone, Federico Ricci
Retina. 2010; 30(6): 903
[VIEW] | [DOI]
9 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Jonathan B. Gunther,Michael M. Altaweel
Survey of Ophthalmology. 2009; 54(3): 372
[Pubmed] | [DOI]
10 Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
Thomas A Ciulla,Philip J Rosenfeld
Current Opinion in Ophthalmology. 2009; 20(3): 166
[Pubmed] | [DOI]
11 Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin®) for treatment of angoid streaks in pseudoxanthoma elasticum
Martin Ganssauge, Helmut Wilhelm, Karl-Ulrich Bartz-Schmidt, Sabine Aisenbrey
Graefe s Archive for Clinical and Experimental Ophthalmology. 2009; 247(12): 1707-1710
[Pubmed] | [DOI]
12 Bevacizumab (Avastin) for the Treatment of Ocular Disease
Gunther, J.B., Altaweel, M.M.
Survey of Ophthalmology. 2009; 54(3): 372-400
13 Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration
Ciulla, T.A., Rosenfeld, P.J.
Current Opinion in Ophthalmology. 2009; 20(3): 166-174
14 Fluorescein angiography characteristics and clinical manifestations of vessel-like stripes features of fundus on 13 cases
Gao, Y.-X., Jiang, X.-Q., Zhang, Y.-Q., Liu, F.-Y.
International Journal of Ophthalmology. 2009; 9(4): 722-724
15 Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: A case series
Donati, M.C. and Virgili, G. and Bini, A. and Giansanti, F. and Rapizzi, E. and Giacomelli, G. and Menchini, U.
Ophthalmologica. 2009; 223(1): 24-27
16 Management of choroidal vascularisation
Lommatzsch, A.
British Medical Journal. 2008; 92(4): 445-446


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
Case Report
Article Figures

 Article Access Statistics
    PDF Downloaded483    
    Comments [Add]    
    Cited by others 16    

Recommend this journal